Supervisor Database Search

Guidance for ICAT Supervisors

The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.

You can read about the ICAT supervisor selection process and eligibility criteria below:

Terms of reference/guide to supervising ICAT Fellows.

You can read the terms of reference for supervisors actively supervising ICAT Fellows below:

Supervisor Database

Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.

← Go back

Full NameProfessor Carel le Roux

Metabolic Medicine

University College Dublin

Webpage:people.ucd.ie

Email hidden; Javascript is required.

Research Fields
  • physiology and non-communicable disease
  • neuroscience and mental health
  • one health
  • nutrition
  • clinical trials
Postgrad Medical Specialties
  • Medicine
  • Psychiatry
  • General Practice
  • Pathology
  • Sports and Exercise Medicine
  • Veterinary Medicine
Medical Subspecialties
  • Adolescent medicine
  • Cardiology
  • Endocrinology
  • Gastroenterology
  • Nephrology
  • Neurology
  • Neurophysiology
  • Neuropsychiatry
  • Physiology
  • Vascular Medicine
My Work

Our lab is focused on translational research to understand the disease of obesity and its impact on humans and animals. We approach obesity as a subcortical brain disease with more than 220 complications. Thus the disease processes in the brain which causes dysregulation of adipocyte mass are of interest, but also the disease processes caused by obesity as reflected by organs such as the heart, kidney, liver, muscle, and bone.

References
1. Purnell JQ, le Roux CW. Hypothalamic control of body fat mass by food intake: The key to understanding why obesity should be treated as a disease. Diabetes Obes Metab. 2024 Feb 14. doi: 10.1111/dom.15478. PMID: 38351898
2. le Roux CW, Miras AD et al. Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial. Lancet. 2024 Jun 8;403(10443):2489-2503. doi: 10.1016/S0140-6736(24)00538-5. PMID: 38782004
3. le Roux CW, Pournaras DJ et al. Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review. Lancet Diabetes Endocrinol. 2024 May 6:S2213-8587(24)00098-6. doi: 10.1016/S2213-8587(24)00098-6. PMID: 38723646
4. le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024 Feb 5:S2213-8587(23)00356-X. doi: 10.1016/S2213-8587(23)00356-X. PMID: 38330987

Potential Projects

We are using treatments such as nutritional therapies, pharmacotherapies, and surgical therapies for obesity to disrupt the complications of obesity such as diabetes, chronic kidney disease, liver disease, heart disease, osteoarthritis, and polycystic ovarian syndrome. We approach this from a one health perspective and thus study humans, horses, dogs, cats, and rodents because many of the disease processes are preserved within species and much can be learnt from working across species.

Scroll to Top